David Koeper, MD
Nephrology · Neenah, WINPI 1487698387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 292 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$792
- AstraZeneca$696
- GSK$634
- Otsuka America Pharmaceutical, Inc.$449
- OPKO Pharmaceuticals, LLC$285
- Vifor Pharma, Inc.$279
- plus $2K from 27 others
What the payments were for
- Consulting fees$1803%
- Food & beverage$5,02495%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 40 | $792 |
| AstraZeneca(2 entities) | 39 | $696 |
| GSK | 31 | $634 |
| Otsuka America Pharmaceutical, Inc. | 25 | $449 |
| OPKO Pharmaceuticals, LLC | 28 | $285 |
| Vifor Pharma, Inc. | 17 | $279 |
| Calliditas Therapeutics US Inc. | 10 | $236 |
| Fresenius USA Marketing, Inc. | 12 | $193 |
| Mallinckrodt Hospital Products Inc. | 8 | $155 |
| Novartis | 7 | $151 |
| Travere Therapeutics, Inc. | 10 | $140 |
| Ultragenyx Pharmaceutical Inc. | 6 | $124 |
| Aurinia Pharma U.S., Inc. | 7 | $120 |
| Ardelyx, Inc. | 6 | $117 |
| Akebia Therapeutics Inc | 5 | $92 |
| Lilly USA, LLC | 4 | $90 |
| Amicus Therapeutics, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Daiichi Sankyo Inc. | 4 | $77 |
| Novo Nordisk | 3 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $56 |
| Bayer | 3 | $54 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $37 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Sanofi | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Cormedix Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$140
How this compares
$5,283 in reported general payments places this provider in the 85th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 58 | $178,599 |
| AuryxiaFerric Citrate | 20 | $77,461 |
| VelphoroSucroferric Oxyhydroxide | 12 | $61,143 |
| Sevelamer Carbonate | 102 | $15,523 |
| Lanthanum Carbonate | 12 | $7,749 |
| Magnesium Sulfate | 53 | $5,182 |
| Clonidine | 26 | $3,410 |
| Calcium Acetate | 30 | $1,562 |
| Labetalol Hcl | 23 | $880 |
| Bumetanide | 18 | $736 |
| Doxazosin Mesylate | 11 | $659 |
| Midodrine Hcl | 15 | $450 |
| Calcitriol | 18 | $374 |
| Amlodipine Besylate | 29 | $311 |
| Irbesartan | 14 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $92 | $77,46120 claims |
| Fresenius USA Marketing, Inc.Velphoro | $193 | $61,14312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 nephrology providers in Wisconsin.
Other nephrology in Neenah
- Atif QureshiNeenah$6K
- Osaid AhmadNeenah$1K
- Imran BalochNeenah$791
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Rishi KoraGlendale$57K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
- Anna GaddyMilwaukee$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.